XML 85 R66.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS - Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended 29 Months Ended
Oct. 19, 2015
USD ($)
Oct. 01, 2015
USD ($)
Apr. 01, 2015
USD ($)
product
$ / shares
Feb. 23, 2015
USD ($)
Jan. 23, 2014
USD ($)
$ / shares
Aug. 05, 2013
USD ($)
Apr. 25, 2013
USD ($)
$ / shares
Feb. 01, 2013
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2014
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2015
USD ($)
Oct. 31, 2015
USD ($)
Feb. 10, 2015
USD ($)
Jul. 07, 2014
USD ($)
Business Combinations                                      
Acquisition-related contingent consideration                   $ 515,600,000   $ 515,600,000 $ 515,600,000 $ 0   $ 515,600,000      
Acquisition of businesses, contingent consideration at fair value                         1,695,800,000 132,600,000 $ 76,100,000        
Acquisition-related costs                         38,500,000 6,300,000 36,400,000        
Acquisition of businesses, net of cash acquired                         (15,457,400,000) (1,102,600,000) (5,253,500,000)        
Pro forma acquisition accounting adjustment on inventory sold subsequent to acquisition date                         130,000,000 20,000,000 370,000,000        
Pro forma acquisition-related costs                         35,000,000 2,000,000 25,000,000        
Amoun                                      
Business Combinations                                      
Aggregate purchase price $ 910,300,000                                    
Payments to acquire business, cash 846,000,000                                    
Acquisition-related contingent consideration 75,000,000                                    
Acquisition of businesses, contingent consideration at fair value 64,000,000                                    
Acquisition-related costs $ 4,000,000                                    
Revenues of acquiree since acquisition date                         48,000,000            
Net earnings (loss), net of tax of acquiree since acquisition date                         (9,000,000)            
Amoun | Other Income (Expense)                                      
Business Combinations                                      
Payments to employees                   12,000,000                  
Sprout                                      
Business Combinations                                      
Aggregate purchase price   $ 1,446,500,000                                  
Purchase Obligation   200,000,000                                  
Acquisition-related contingent consideration   422,000,000                                  
Acquisition of businesses, contingent consideration at fair value   495,000,000                                  
Acquisition-related costs   4,000,000                                  
Aggregate purchase price   530,000,000                                  
Contingent consideration commencement, sales revenue   1,000,000,000                                  
Net earnings (loss), net of tax of acquiree since acquisition date                         (37,000,000)            
Sprout | Subsequent event                                      
Business Combinations                                      
Aggregate purchase price                 $ 500,000,000                    
Salix                                      
Business Combinations                                      
Aggregate purchase price                   13,132,000,000   13,132,000,000 13,132,000,000     13,132,000,000      
Acquisition-related contingent consideration                   500,000,000   500,000,000 500,000,000     500,000,000      
Acquisition-related costs                       15,000,000 15,000,000            
Revenues of acquiree since acquisition date                         1,280,000,000            
Aggregate purchase price     $ 13,132,000,000                                
Net earnings (loss), net of tax of acquiree since acquisition date                         (302,000,000)            
Per Share Consideration (in dollars per share) | $ / shares     $ 173.00                                
Number of products in product portfolio | product     20                                
Common stock, par value (in usd per share) | $ / shares     $ 0.001                                
Possible contingent consideration                   650,000,000   650,000,000 650,000,000     650,000,000      
Salix | Restricted Stock                                      
Business Combinations                                      
Per Share Consideration (in dollars per share) | $ / shares     $ 173.00                                
Dendreon Corporation                                      
Business Combinations                                      
Payments to acquire business, cash       $ 495,000,000                              
Acquisition of businesses, net of cash acquired       (415,000,000)                              
Cash Acquired from Acquisition       80,000,000                              
Cash consideration paid for B&L’s unvested stock options       $ (50,000,000)                              
Marathon Pharmaceuticals, LLC                                      
Business Combinations                                      
Acquisition-related contingent consideration                   35,000,000   35,000,000 35,000,000     35,000,000      
Aggregate purchase price                                   $ 286,000,000  
Liabilities assumed                                   $ 64,000,000  
Possible contingent consideration                   200,000,000   200,000,000 200,000,000     200,000,000      
2015 Acquisitions                                      
Business Combinations                                      
Aggregate purchase price                   1,412,200,000   1,412,200,000 1,412,200,000     1,412,200,000      
Acquisition of businesses, contingent consideration at fair value                         191,000,000            
Acquisition-related costs                         16,000,000            
Revenues of acquiree since acquisition date                         771,000,000            
Net earnings (loss), net of tax of acquiree since acquisition date                         208,000,000            
Brodalumab                                      
Business Combinations                                      
Upfront payment   $ 100,000,000                                  
Brodalumab | Pre-launch Milestone Payments                                      
Business Combinations                                      
Possible contingent consideration                   170,000,000   170,000,000 170,000,000     170,000,000 $ 170,000,000    
Brodalumab | Sales Based Milestone Payments                                      
Business Combinations                                      
Possible contingent consideration                   175,000,000   175,000,000 $ 175,000,000     175,000,000 $ 175,000,000    
PreCision                                      
Business Combinations                                      
Acquisition-related contingent consideration                                     $ 25,000,000
Aggregate purchase price                                     $ 459,000,000
PreCision | Other Income (Expense)                                      
Business Combinations                                      
Post-combination expense                     $ 20,000,000                
Solta                                      
Business Combinations                                      
Aggregate purchase price         $ 293,000,000                            
Per Share Consideration (in dollars per share) | $ / shares         $ 2.92                            
Aggregate principal amount of notes repurchased         $ 44,000,000                            
Philidor                                      
Business Combinations                                      
Net revenue of acquiree as a percentage of consolidated revenue                         5.00%            
2014 Acquisitions                                      
Business Combinations                                      
Aggregate purchase price                   $ 1,347,100,000   $ 1,347,100,000 $ 1,347,100,000     1,347,100,000      
Acquisition of businesses, contingent consideration at fair value                           132,000,000          
B&L                                      
Business Combinations                                      
Aggregate purchase price                           4,613,300,000          
Acquisition-related costs                               $ 13,000,000      
Aggregate purchase price           $ 4,613,300,000                          
Cash Acquired from Acquisition           149,000,000                          
Cash consideration paid for B&L’s unvested stock options           (4,300,000)                          
Enterprise value           $ 8,700,000,000                          
Obagi Medical Products, Inc                                      
Business Combinations                                      
Aggregate purchase price             $ 437,000,000                        
Per Share Consideration (in dollars per share) | $ / shares             $ 24.00                        
Natur Produkt                                      
Business Combinations                                      
Aggregate purchase price               $ 150,000,000                      
Contingent refund of purchase price               $ 20,000,000                      
2013 Other Business Combinations                                      
Business Combinations                                      
Aggregate purchase price                           $ 898,100,000 898,000,000        
Acquisition-related contingent consideration                             $ 59,000,000